# EDGAR Filing Document

**Accession Number:** 0000880242
**File Stem:** 0001437749-26-007044
**Filing Date:** 2026-3
**Character Count:** 12613
**Document Hash:** 72b96f32c6df19eaabb48e22b97880f4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-007044.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001437749-26-007044

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 27

**CONFORMED PERIOD OF REPORT**: 20260305

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOLARGO, INC.
- **CENTRAL INDEX KEY:** 0000880242
- **STANDARD INDUSTRIAL CLASSIFICATION:** CHEMICALS & ALLIED PRODUCTS [2800]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 650159115
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19709
- **FILM NUMBER:** 26725566

**BUSINESS ADDRESS:**
- **STREET 1:** 14921 CHESTNUT ST.
- **CITY:** WESTMINSTER
- **STATE:** CA
- **ZIP:** 92683
- **BUSINESS PHONE:** 888 400-2863

**MAIL ADDRESS:**
- **STREET 1:** 14921 CHESTNUT ST.
- **CITY:** WESTMINSTER
- **STATE:** CA
- **ZIP:** 92683

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NUWAY MEDICAL INC
- **DATE OF NAME CHANGE:** 20030205

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NUWAY ENERGY INC
- **DATE OF NAME CHANGE:** 20010815

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LATIN AMERICAN CASINOS INC
- **DATE OF NAME CHANGE:** 19960520

?xml version='1.0' encoding='ASCII'? blgo20260305_8k.htm

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 8-K** 

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

Date of Report (Date of earliest event reported): March 5, 2026

---

| |
|:---|
| **BioLargo, Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-19709** | **65-0159115** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **14921 Chestnut St., Westminster, California**  | **92683** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: (888) 400-2863

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock | BLGO | OTCQX |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.**

BioLargo, Inc., intends to present the slides attached as <u>Exhibit 99.1</u>, which are incorporated herein by reference, on March 5, 2026, 9:00 AM Pacific Time, at a webcast investor conference. BioLargo, Inc., published the press released attached as <u>Exhibit 99.2</u>, which is incorporated by this reference, on March 5, 2026.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the exhibits to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading "Safe Harbor Act" in the exhibits attached hereto.

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Slide deck presentation](ex_929177.htm) |
| 99.2 | [Press release](ex_929178.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 5, 2026 | BIOLARGO, INC. | BIOLARGO, INC. |
|  | By: | /s/ Dennis P. Calvert |
|  |  | Dennis P. Calvert |
|  |  | President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![slide1.jpg](slide1.jpg)

------

![slide2.jpg](slide2.jpg)

------

![slide3.jpg](slide3.jpg)

------

![slide4.jpg](slide4.jpg)

------

![slide5.jpg](slide5.jpg)

------

![slide6.jpg](slide6.jpg)

------

![slide7.jpg](slide7.jpg)

------

![slide8.jpg](slide8.jpg)

------

![slide9.jpg](slide9.jpg)

------

![slide10.jpg](slide10.jpg)

------

![slide11.jpg](slide11.jpg)

------

![slide12.jpg](slide12.jpg)

## Exhibit 99.2

**Exhibit 99.2**

**BioLargo Reports Annual 2025 Operating and Financial Results**

***A Year of Disciplined Execution as BioLargo Gained Commercialization for Several Business Segments***

***$3.9 Million Cash Balance at Year End***

**Westminster, CA / ACCESS Newswire / March 5, 2026** – BioLargo, Inc. (OTCQX: BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today announced that its Annual Report for the year ended December 31, 2025. To view the filing in its entirety, please see:

<u>https://www.biolargo.com/sec-filings</u>.

BioLargo, Inc. President and CEO Dennis P. Calvert, commented, "2025 was a year of great accomplishment and great adversity, where, on the one hand, we managed through the termination of our largest customer's license and that loss of revenue, and, on the other, grew our engineering services revenue by 98%, and advanced our other business projects and divisions. We did what we said we would do, making significant commercial advancements in several business segments, setting the stage for revenues in new areas in 2026."

Calvert, concluded, "These accomplishments produced increased enterprise valuations in our Clyra Medical Technologies and Cellinity Battery divisions, both of which raised capital in 2025. Our Company remains very healthy with $3.9 million cash balance and varying shots on goal across several industries. We are as optimistic as ever with our emerging solutions surrounding surgical products, water treatment for the global PFAS contamination crisis and battery energy storage technology. We look forward to continuing our commercialization efforts and ramp in 2026."

**<u>2025 and Subsequent 2026 Highlights</u>:**

● **BioLargo Subsidiary BEST Featured in Chemical Engineering Magazine for PFAS Breakthrough** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o <u>https://www.biolargo.com/post/biolargo-subsidiary-best-featured-in-chemical-engineering-magazine-for-pfas-breakthrough</u> 

● **BioLargo Subsidiary Clyra Medical Highlights Key Opinion Leader Presentation of Exceptional ViaCLYR(TM) Clinical Results at Leading Wound Care Symposium** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o <u>https://www.biolargo.com/post/biolargo-subsidiary-clyra-medical-highlights-key-opinion-leader-presentation-of-exceptional-viaclyr</u> 

● **BioLargo Subsidiary Clyra Medical Technologies Secures First Stocking Order with Advanced Solution for ViaCLYR(TM) Wound Irrigation Solution** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o <u>https://www.biolargo.com/post/biolargo-subsidiary-clyra-medical-technologies-secures-first-stocking-order-with-advanced-solution-f</u> 

● **BioLargo Installs AEC PFAS Treatment System at Lake Stockholm, New Jersey** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o <u>https://www.biolargo.com/post/biolargo-installs-aec-pfas-treatment-system-at-lake-stockholm-new-jersey</u> 

**<u>Financial highlights</u>**

● Assets at December 31, 2025, were $8,311,000, versus $6,785,000 in liabilities, which included $3,883,000 in cash and cash equivalents

● Revenues for 2025 were $7,765,000, versus $17,779,000 in 2024 – engineering services revenues from third parties increased from $1,017,000 to $1,998,000

● Net loss in 2025 was $15,189,000, versus $4,347,000 in 2024

● Cash flow from financing activities was $2,051,000 for BioLargo Inc., $5,745,000 for Clyra Medical, and $425,000 for BioLargo Energy

**About BioLargo, Inc.**

BioLargo, Inc. (OTCQB: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at <u>www.BioLargo.com</u>.

**Contact Information**

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

**Safe Harbor Act**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.